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ABSTRACT 
Aim: Infections in early childhood are common reasons to seek medical attention. This study 
compares the prevalence of infections, and the use of antibiotics and antipyretic-analgesics, in 
children from Finland, Estonia, and Russian Karelia. 
Methods: Children with a genetically increased risk for type 1 diabetes (N=797) were observed from 
birth up to 3 years of age. Illnesses and medications were reported by parents continuously. All 
reported infections, antibiotics, and antipyretic-analgesics were compared between Finland and 
Estonia, and to a lesser extent with Russian Karelia, due to poor study compliance.  
Results: Compared to Estonians, Finns reported more infections during the first and second years of 
life. During the follow-up Finnish children had 10 infections while Estonians only had 8 (p<0.001). 
Finns also used more antibiotics and antipyretic-analgesics in each year during the follow-up. 
Russian Karelians reported the lowest frequency of infections and the most infrequent use of 
antibiotics and antipyretic-analgesics in the first 2 years of life. 
Conclusion: Infections and the use of antibiotics and antipyretic-analgesics in early childhood were 
most frequent in Finland, where socio-economic conditions are the most developed and microbial 
encounters are sparse. This may reflect on the hygiene hypothesis; a less effective immune system 
that allows normally harmless microbes to attack and cause clinical infections.  
 
Abbreviations 
CD, celiac disease 
HLA, human leukocyte antigen 
ICD, International Classification of Diseases 
T1D, type 1 diabetes 
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Key notes:  
 The aim was to compare the frequency of infections, and the use of antibiotics and 
antipyretic-analgesics, in children from three countries with significant differences in socio-
economic conditions. 
 Compared to Estonians, Finns reported more infections during the first and second years of 
life, while Russian Karelians reported the lowest number of infections. 
 Antibiotics and antipyretic-analgesics were used most frequently in Finland, even in relation 
to infection frequencies. 
 
INTRODUCTION 
The majority of children suffer from common childhood infections several times during their first 
years of life. Viral respiratory infections, especially those caused by rhinoviruses, are the most 
common of such infections (1,2). In spite of the increased awareness regarding the risks caused by 
antibiotic resistance, antibiotics are frequently prescribed based on obscure clinical pictures, without 
knowledge of the causative pathogens (3,4). The lax use of broad-spectrum antibiotics is driving a 
host of microbes towards multiresistance, which is already causing severe clinical problems 
worldwide (5). Recurrent use of systemic antibiotics disturbs the balance of the intestinal 
microbiota, causing dysbiosis early in life (6,7), the long-term consequences of which are still 
unknown. So far, use of antibiotics in early life has been reported to be associated with an increased 
risk for future asthma (8,9), juvenile idiopathic arthritis (10), neurocognitive disorders (11), and 
obesity (12). 
The hygiene hypothesis (13) suggests that the loss of beneficial microbial encounters in early 
life may inhibit the normal maturation of the developing immune system, leading to aberrant 
immune reactions towards harmless antigens, loss of self-tolerance, and outbreak of immune 
mediated diseases. This hypothesis was tested in the DIABIMMUNE study, in a cohort of Finnish, 
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Estonian, and Russian Karelian children with human leukocyte antigen (HLA)-conferred susceptibility 
to type 1 diabetes (T1D). Our current data presents differences between these three countries 
regarding childhood infections and their medications. Finland, Estonia, and Russian Karelia share 
similar seasonal variation, exposure to sunlight, and outdoor temperatures, but differ from each 
other in their socio-economic circumstances and standard of hygiene (14). Notably, differences 
between these three countries in the incidence of several immune-mediated diseases, such as T1D, 
celiac disease (CD), and atopic diseases, are conspicuous (15-19). The study area in Espoo, Finland, 
presents a fully industrialized and westernized socio-economic environment with high gross 
domestic product (GDP) per capita and remarkably high standard of living, while Russian Karelia 
struggles with poor socio-economic conditions. Estonia positions economically between the two 
other countries, but has since gaining its independence in 1991 continued its rapid socio-economic 
growth and undergone intense changes in the general standard of living. 
 
METHODS 
Study population. All newborn infants with parental consent born between September 2008 and 
February 2011 in one hospital in Finland, two hospitals in Estonia, and two hospitals in Russian 
Karelia were screened for HLA-conferred susceptibility T1D (Figure 1). Children carrying these risk-
genotypes were invited to the birth cohort of the DIABIMMUNE study and followed prospectively 
from birth up to the age of 3 years. From the original 835 children who enrolled in the study, 38 
children were excluded due to incomplete data [HLA misclassification (n = 7) and no questionnaires 
answered (n = 31)], leaving 797 children (nFIN=386 nEST=322, and nRUS=89) to be included in the 
current study. The study details have been described elsewhere (20). Briefly, families reported 
continuously the participating child’s infections, use of medications, and other life events in a study 
diary. The participants attended clinical visits at the age of 3, 6, 12, 18, 24 and 36 months for clinical 
examination, sampling of biological specimens, and for presentation of the study diary.  
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Nearly 70% of the participants (n=557, 69.9%) completed the follow-up. The drop-out rates 
were similar in Finland and Estonia (21.8% and 22.0%, respectively), but only four participants from 
Russian Karelia completed the study (drop-out rate 95.5%; Figure 1). Because of this unequal study 
compliance and remarkable differences in the original cohort sizes, comprehensive analyses could 
performed only for Finland and Estonia. A shorter, descriptive analysis about results from Russian 
Karelia was carried out.  
The local ethics committees (Ethics committee, Helsinki and Uusimaa Hospital District; Ethics 
Review Committee on Human Research of the University of Tartu; and Ethics committee, Ministry of 
Health and Social Development, Karelian Republic of the Russian Federation) had approved the 
study and parents had provided written informed consents before starting the study procedures. 
HLA genotyping. The cord blood samples from the newborn infants were analysed for the presence 
of HLA DR/DQ genotypes associated with increased risk for T1D with a polymerase chain reaction-
based lanthanide-labelled hybridization method, as previously described (21,22). Children positive 
for DR3-DQ2 (DQA1*05-DQB1*02) and/or DR4-DQ8 (DRB1*04:01/2/4/5/8-DQB1*0302/4) without 
protective haplotypes (23) were eligible for the study. The participants were classified into HLA risk 
groups according to presence of the risk haplotypes; DR3-DQ2/DR4-DQ8 heterozygosity indicating 
highest risk for T1D, and DR4-DQ8/X (X=DR4-DQ8 or a neutral haplotype) or DR3-DQ2/Y (Y=DR3-DQ2 
or a neutral haplotype) indicating a moderate risk. 
Classification of infections. Illnesses reported by parents in the DIABIMMUNE diary were categorized 
according to the International Classification of Diseases 10th revision (ICD-10) and transferred into 
the study database by the study staff. Only illnesses showing clear signs of infections were included 
in this study (i.e. ICD-10 codes indicating infectious diseases and episodes with only fever but 
without a local infection focus). Infectious illnesses reported within a week from each other were 
classified according to the most severe diagnostic code as respiratory, gastrointestinal, other, and 
unlocalized febrile infection episodes (20,24). As an exception, episodes of otitis media reported 
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within four weeks were classified into one episode of reoccurring otitis media. This approach was 
chosen to reduce overestimation of microbe encounters leading to infections. Fever was defined as 
peripheral temperature higher than 37.5°C. 
Classifications of medications. The use of medications was reported by parents with brand names 
and entered into the DIABIMMUNE database by the study staff. Only the use of systemic antibiotics 
and antipyretic-analgesics were included in the current study. Parents reported the child’s age at the 
start of the drug treatment, its duration, and the reason for it. Antibiotics were classified according 
to the active ingredient as aminoglycosides, cephalosporins, macrolides, penicillins, combinations of 
sulfonamides and trimethoprim, and other antibiotics. Antipyretic-analgesics were analysed 
according to the active ingredient (paracetamol, ibuprofen, naproxen, and acetylsalicylic acid).  
Statistical analyses. Data were analysed with IBM SPSS Statistics, version 22.0 and 25.0 (IBM Corp., 
Armonk, N.Y., USA). The normal distribution of the data was tested with the Kolmogorov-Smirnov 
test. Comparisons between categorical variables were performed using cross-tabulation and Chi-
square test. One-way ANOVA test with Bonferroni post hoc test was used for parametrically 
distributed variables (mean, standard deviation (SD)). The Mann-Whitney U-test and Kruskal-Wallis 
test were applied for comparisons of non-parametric variables between groups, and these results 
are presented as medians and interquartile range (IQR; with the 25th to 75th percentile). In some 
analyses medians nor the IQRs differed, although the distributions differed significantly between 
groups. These results are marked with the significant p value and the IQRs are replaced with ranges; 
no mean ranks are reported. A p-value <0.05 was considered to indicate statistical significance. 
Each 6 and 12-month interval was analysed separately and children who had dropped out 
from the study were not considered in the analyses after the drop-out. A child was regarded as a 
drop-out if he/she had dropped out of the study more than 1 month prior to the end of that interval, 
i.e. children who dropped out at the age of ≥11 months were included in analyses of the first year of 
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life. This 1-month rule was selected because children, who dropped out a few weeks before the 
interval’s actual endpoint, were considered to have reported close to all data at this point. 
 
RESULTS 
The descriptives of the study cohorts are shown in Table 1. Finnish infants carried the DR3-DQ2/Y 
genotype less frequently, had an older gestational age, and their mothers were older at the delivery 
of the offspring, compared to Estonians and Russian Karelians. Russian Karelians had the lowest 
number of siblings at birth (full- and half siblings, twins included) and they were taller at birth than 
their Finnish and Estonian peers. These background characteristics of the participants did not explain 
any of the results below. The number of infections in each year and cumulative during the entire 
follow-up did not differ between HLA risk groups. 
A total of 6092 infection episodes were reported during the follow-up, out of which 48.1% 
were diagnosed by heath care providers (Finland 51.1%, Estonia 41.2%, and Russian Karelia 95.0%). 
Close to all children who completed the study had at least one infection during the follow-up 
(99.8%). The majority of reported infections were respiratory (76.4%), followed by gastrointestinal 
(8.7%), unlocalized febrile episodes (7.9%), and other infections (7.0%). Fever was reported in 47.3% 
of the episodes. A total of 1707 antibiotic treatments and 2053 episodes of the use of antipyretic-
analgesic medications were reported. Among those children who completed the study, 75.6% and 
83.1% had used antibiotics and antipyretic-analgesics, respectively, during the follow-up. The most 
frequently used antibiotics were penicillins (62.6%), followed by macrolides (12.9%), combinations of 
sulfonamides and trimethoprim (10.9%), cephalosporins (11.4%), aminoglycosides (1.2%), and other 
antibiotics (1.1%). Among antipyretic-analgesics, paracetamol was used most frequently (76.3%; 
naproxen 15.8%, ibuprofen 7.7%, and acetylsalicylic acid 0.2%). The use of naproxen was only 
reported in Finland (Table 2).  
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Finland vs. Estonia 
Compared to Estonians, Finns reported more infections during the first and second year of life (1st 
year: medians 3.0 (IQR 2.0-5.0) vs. 3.0 (1.0-4.0), p=0.008; 2nd year: 4.0 (3.0-6.0) vs. 3.0 (2.0-4.0), 
p<0.001). In the first year of life, Finns reported more respiratory infections (p<0.001) and Estonians 
more other infections (p=0.004), compared to the respective other country. During the second year 
of life, differences were only seen in the number of respiratory infections, with Finnish children 
experiencing more of such infections (p<0.001). In the third year of life, there was no difference in 
the number of infections per child between the countries, but when looking at specific infection 
types, Finns reported more unlocalized febrile episodes (p<0.001). The number of infections per 
child per each 6-month interval are shown in Figure 2. In the first and third year of life both countries 
reported similar proportions of children having at least one infection (Finns 91.4% and 84.4%, and 
Estonians 88.6% and 86.9%, respectively), but in the second year Finns reported a higher proportion 
of such children (96.1% vs 91.7%, p=0.022). During the entire follow-up, children from Finland had a 
median of ten (6.8-14.0) infections while Estonians had eight (6.0-11.0; p<0.001; Figure 3). However, 
Estonian children who had at least one infection during the follow-up tended to have their first 
infection at a slightly younger age than their Finnish peers [4.4 (2.5-6.7) vs. 5.0 (3.1-7.0) months, 
p=0.057]. 
The parents reported that the first antibiotic treatment and the first use of an antipyretic-
analgesic occurred at a younger age in the Finnish children than in the Estonian participants (1st 
antibiotic: 10.0 (6.0-16.0) vs. 12.0 (6.5-20.0) months, p=0.017; 1st antipyretic-analgesic: 5.5 (3.0-
10.0) vs. 10.0 (6.0-15.6) months, p<0.001). In each year during the follow-up, Finnish children were 
given more antibiotics and antipyretic-analgesics than their Estonian peers (Figure 4). During the 
entire follow-up, children from Finland were given on an average  three (1-6) antibiotic courses and 
four (2-6) courses of antipyretic-analgesics, while Estonian children were exposed to only one (0-3) 
antibiotic and one (0-3) antipyretic-analgesic (p<0.001 regarding both drug classes). Macrolides were 
used for longer periods of time in Estonia than in Finland [7 (5-7) vs. 3 (3-5) days, p<0.001], but no 
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differences in the duration of treatment were seen in the other groups of antibiotics. Antipyretic-
analgesics were also administered for longer periods in Estonia than in Finland [3 (2-3) vs. 2 (1-3) 
days, p=0.005]. The more frequent use of medications in Finland was not explained by the higher 
number of infections, since Finns used more antibiotic  courses per infection [0.29 (0.11-0.50) vs. 
0.14 (0.00-0.31), p<0.001] and per infections diagnosed by a healthcare provider [0.60 (0.33-1.00) vs 
0.40 (0.00-0.80), p<0.001), as well as more antipyretic-analgesics per infection [0.38 (0.23-0.60) vs. 
0.17 (0.00-0.38), p<0.001] and per infections with fever [1.00 (0.46-1.50) vs. 0.39 (0.14-0.75), 
p<0.001].  
Russian Karelia 
Russian Karelians reported their first infection at an age of 6.6 (4.3-9.9) months, which is older than 
the ages at the first infections in Finland (p=0.034) and Estonia (p=0.002). During the first year of life 
only 65.4% of Karelians reported at least one infection and during the second year 60.0%. Karelians 
reported a median of one infection both in the first and in the second year of life, which is less than 
the number of infections in Finland and Estonia (p<0.001 compared to Finns and Estonians in both 
years). Differences were seen in the number of respiratory infections during both years compared to 
Finland and Estonia, and in the number of other infections during the first year between Russian 
Karelia and Estonia. Since only four Karelian children remained in the study until the age of 3 years, 
no analyses were possible during the third year. 
The parents of only 17 children (19.1%) from Russian Karelia reported the use of any 
antibiotics. Compared to the two other countries, Karelians were exposed to less antibiotics during 
the first and second year of life (significant between Finland and Russian Karelia; p=0.001 and 
p<0.001, respectively), but the first antibiotic was administered at a slightly younger age.  
Karelian children, in whom the parents reported the use of antipyretic-analgesics (n=17, 
19.1%) were older than their Finnish peers [10.0 (8.5-13.5) vs. 5.5 (3.0-10.0) months, p=0.001] and 
about the same age as their Estonian peers at the first introduction of paracetamol or ibuprofen. 
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Karelians were exposed to antipyretic-analgesics less frequently than Finns during the first (p<0.001) 
and second year (p=0.001) of life.  
 
DISCUSSION 
In the current study we found that Finnish children experienced more early childhood infections up 
to the age of 2.5 years compared to Estonians and Russian Karelians. This was the case especially 
regarding respiratory infections. Finnish children also used significantly more antibiotics and 
antipyretic-analgesics during the entire 3-year follow-up.  
These results are consistent with our hypothesis, but they do not explain the reason for it. 
Since these geographically adjacent areas have resembling climatic conditions and quite similar 
prevalences of HLA-genotypes, but notable differences in the incidences of immune-mediated 
diseases, the suspicion shifts toward the immune system. With our study design, we could only 
evaluate microbe exposures leading to clinical infections; subclinical infections could not be 
assessed. Nonetheless, Russian schoolchildren have been shown to be exposed to microbes, such as 
Helicobacter pylori, hepatitis A, Coxsackievirus B4, and Toxoplasma gondii, more frequently than 
Finnish children (25). Russian Karelian young children have also been shown to have a more mature 
immune response to microbe encounters (26). This demonstrates how higher frequencies of clinical 
infections are not simply explained by the higher number of microbe encounters. As the hygiene 
hypothesis suggests, the developing immune system requires microbial encounters to guide its 
maturation towards self-tolerance and its ability to defend the host against pathogens. The lack of 
beneficial microbe encounters due to a westernized lifestyle or imbalances in the intestinal 
microbiome caused by antibiotic treatments (27), could be factors altering the education and 
maturation of the immune system, and thus leading to more clinical infections, and possible even to 
immune-mediated diseases later in life. 
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As expected, paracetamol was the most commonly used antipyretic-analgesic medication. 
Only 26 children had used paracetamol up to the age of 3 months. Acetylsalicylic acid was reported 
to be used in Finland and Estonia by only three children (one used it twice) for fever, flu, and 
postoperatively at 6 to 30 months of age. This shows that acetylsalicylic acid no more is the primary 
antipyretic-analgesic for children, which could potentially be explained by increased awareness of 
Reye’s syndrome. Naproxen was reported to be used only in Finland. How this might explain the 
results remains unclear, but compared to ibuprofen and paracetamol, naproxen has a more 
longstanding and a stronger immunomodulatory effect. The more extensive use of antibiotics and 
antipyretic-analgesics in Finland was not explained by the higher number of infections, since Finnish 
children used more of both drug classes per infection episode. 
The strength of our study is that the subjects are from three countries with remarkable 
differences in socio-economic conditions, but with similar HLA-genotypes. Another asset is that 
infections and medications were monitored continuously by parents. By inspecting medical records 
and records of prescribed medications, the number of illnesses common in childhood, such as 
common cold and other mild infections, and the use of over-the-counter medicines, such as 
antipyretic-analgesics, would have been underestimated. However, since a total of 52% of the 
infections were not diagnosed by a healthcare provider, subjective and cultural differences in 
parental conceptions of symptoms are possible. The high proportion of infections diagnosed by a 
healthcare provider in Russian Karelia (95%, vs 51% in Finland and 41% in Estonia) reflects on 
differences in the healthcare systems, since in Russia a family doctor is consulted at a lower 
threshold. 
This study has some limitations. All study subjects carried HLA-conferred susceptibility to T1D, 
and the results might therefore not apply to the general population. Since the HLA genotypes 
included are known to predispose to autoimmune disorders, these children might by default have a 
weaker immune system or a less favourable intestinal microbiome, which in turn may be reflected in 
a higher predisposition to clinical infections. However, these HLA genotypes are common in the 
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general population and only a small proportion of people carrying these genotypes develop T1D. We 
screened almost 9000 children and 19% of them carried predisposing genotypes (Finland 23%, 
Estonia 16%, and Russian Karelia 17%). Two children were diagnosed with T1D during the follow-up, 
and by September 2018 12 children (1.5%) have been diagnosed with T1D. Children who develop 
prediabetes and T1D have been shown to have more infections in early childhood, especially during 
the first year of life, both compared to the general population and to healthy children with HLA-
conferred disease susceptibility (20,28-31).  
The low enrolment rate and the high drop-out rate in Russian Karelia did not allow us to 
perform proper analyses between all three countries. Karelian children used clearly less antibiotics 
and a broader spectrum of different antibiotics, which fits into earlier observations about more 
conservative antibiotic use in Russia (32). Russian Karelians tended to be treated with homeopathic 
medications instead of antibiotics and antipyretic-analgesics, which may explain some of the 
differences in the reported frequencies of antibiotics and antipyretic-analgesics. We recommend 
that the results regarding Russian Karelia should be interpreted critically since, in addition to the 
small study cohort, Karelians reported no neonatal infections (age <0.5 months) and no post term 
births (>42 weeks). In contrast to Finland and Estonia, antibiotics can often be bought without a 
prescription in Russia (33). This did not, however, result in a more extensive use of antibiotics in 
Karelia among young children. 
In conclusion, we found that children from Finland have more infections and they use more 
antibiotics and antipyretic-analgesics in early childhood, compared to Estonians and Russian 
Karelians. In line with the hygiene hypothesis, this could indicate a weaker immune system in Finns, 
due to too sparse microbe encounters when the immune system is maturating. However, other 
factors, such as environmental and genetic, cannot be ruled out. The extensive use of antibiotics, 
particularly in Finland, is concerning. Antibiotics should not be used without appropriate diagnostics, 
since childhood infections is mostly caused by viruses, and the extensive use of antibiotics leads to 
increasing microbe resistance and unfavourable changes in the gut microbiome. 
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Tables 
  
Table 1  Descriptive characteristics of the study cohorts 
 
 
Finland 
n=386 
Estonia 
n=322 
Russian Karelia 
n=89 
Proportion of males (%) 50.5 51.2 57.3 
Maternal age at delivery, years (mean, SD) a 31.2 (4.5) 28.9 (5.7) 27.6 (4.8) 
Number of siblings at birth (median, range) b 0 (0-6) 1 (0-6) 0 (0-3) 
Gestational age, weeks (median, IQR) c 40.3 (39.3-41.0) 40.0 (39.0-40.9) 40.0 (39.0-40.0) 
Birth weight, g (mean, SD) 3565.9 (473.2) 3579.2 (511.0) 3521.3 (477.4) 
Birth length, cm (median, IQR) d 51.0 (49.0-52.0) 51.0 (49.0-52.0) 52.0 (51.0-53.5) 
Birth head circumference, cm (median, IQR) 35.0 (34.0-36.0) 35.0 (34.0-36.0) 35.0 (34.0-36.0) 
Caesarean section (%) 9.6 10.6 14.6 
HLA risk group (%) e    
 DR3-DQ2 / DR4-DQ8 9.1 9.6 6.7 
 DR4-DQ8 / X f 39.1 28.9 30.3 
 DR3-DQ2 / Y g 51.8 61.5 62.9 
 
a
 significant between Finland & Estonia (p<0.001), and Finland & Russian Karelia (p<0.001) 
b
 significant between Finland & Russian Karelia (p=0.004), and Estonia & Russian Karelia (p<0.001) 
c
 significant between Finland & Russian Karelia (p=0.001) 
d
 significant between Finland & Russian Karelia (p<0.001), and Estonia & Russian Karelia (p<0.001) 
e
 p=0.041 with Chi-square test 
f 
X=DR4-DQ8 or a neutral haplotype
 
g
 Y=DR3-DQ2 or a neutral haplotype 
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Table 2 Number (%) of all reported infection episodes, antibiotics, and 
antipyretic-analgesic medications in each country. 
  Finland Estonia Russian Karelia 
Infection episodes 3481 (100) 2470 (100) 141 (100) 
 Respiratory 2734 (78.5) 1808 (73.2) 114 (81) 
 Gastrointestinal 267 (7.7) 254 (10.3) 10 (7) 
 Other 191 (5.5) 223 (9.0) 11 (8) 
 Unlocalized febrile 289 (8.3) 185 (7.5) 6 (4) 
Antibiotics 1175 (100) 499 (100) 33 (100) 
 Aminoglycosides 1 (0.1) 19 (3.8) 1 (3) 
 Cephalosporins 136 (11.6) 51 (10.2) 7 (21) 
 Macrolides 180 (15.3) 33 (6.6) 7 (21) 
 Penicillins 705 (60.0) 351 (70.3)  12 (36) 
 
Sulfonamides and 
trimethoprim 
144 (12.3) 41 (8.2) 0 (0) 
 Other antibiotics 9 (0.8) 4 (0.8) 6 (18) 
Antipyretic-analgesics 1467 (100) 557 (100) 29 (100) 
 Paracetamol 1032 (70.3) 513 (92.1) 21 (72) 
 Ibuprofen 108 (7.4) 43 (7.7) 8 (28) 
 Naproxen 324 (22.1) 0 (0.0) 0 (0) 
 Acetylsalicylic acid 3 (0.2) 1 (0.2) 0 (0) 
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Figure legends 
 
Figure 1. Participating children from each county; from HLA-screening to those who completed the 
follow-up. 70% completed the follow-up. Drop-out rates were 22% in Finland and Estonia, and 96% 
in Russian Karelia.  
Figure 2. Mean number of all infections per 6-month intervals (drop-outs excluded at each interval). 
Comparisons were made using Mann-Whitney U test, and significant p-values are marked (**p<0.01 
and ***p<0.001). 
Figure 3. Mean number of all reported infections during the entire follow-up. Children who dropped 
out before the end of the study were excluded. Infections were classified into respiratory, 
gastrointestinal, other, and unlocalized febrile infection episodes according to the most severe ICD-
10 code. Comparisons were made using Mann-Whitney U test, and significant p-values are marked 
(*p<0.05, **p<0.01, and ***p<0.001). 
Figure 4. Mean number of all antibiotics and antipyretic-analgesics reported per year of participating 
in the study. Comparisons were made using Mann-Whitney U test, and significant p-values are 
marked (*p<0.05 and ***p<0.001). 
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Screened for HLA genotypes 
HLA eligible  
(% of all screened) 
Enrolled in the study 
Included in this study * 
Still in the study after the 1st year 
of life 
Still in the study after the 2nd year 
of life 
(% of those included in the study)   
Completed the 3 year follow-up 
(% of those included in the study)  
* Participants (n=38) were excluded because of missing data. 
Finland Russian Karelia Estonia Total 
2714 3044 3105 8863 
713 (23.0) 426 (15.7) 514 (16.9) 1653 (18.7) 
387 330 118 835 
311 (80.6) 276 (85.7) 20 (22.3) 607 (76.2) 
302 (78.2) 251 (78.0) 4 (4.5) 557 (69.9) 
386 322 89 797 
337 (87.3) 297 (92.2) 52 (58.4) 686 (86.1) 
Figure 1  
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Figure 2  
 
 
Figure 3  
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Figure 4  
 
 
 
 
